Start Date
November 30, 1999
Primary Completion Date
September 30, 2007
Study Completion Date
September 30, 2007
fluorouracil
leucovorin calcium
semaxanib
New York Medical College, Valhalla
Hematology/Oncology Associates of NE Pennsylvania, P.C., Scranton
Johns Hopkins Oncology Center, Baltimore
Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh
Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Dial Research Associates, Inc., Nashville
Associates in Oncology & Hematology, Chattanooga
Michigan State University, East Lansing
University of Wisconsin Comprehensive Cancer Center, Madison
University of Minnesota Cancer Center, Minneapolis
Mary Bird Perkins Cancer Center, Baton Rouge
Presbyterian Hospital of Dallas, Dallas
Tower Hematology Oncology Medical Group, Los Angeles
Scripps Clinic, La Jolla
St. Francis Hospital, San Francisco
Queen's Medical Center, Honolulu
Alabama Oncology, LLC, Montgomery
Office of Richard Shapiro, Benjamin Stafford, and Sharon J. Yee, Arcadia
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Cancer Center of Boston, Boston
APN-IMPATH Research Corporation, Fort Lee
Hackensack University Medical Center, Hackensack
Presbyterian Healthcare, Charlotte
University of Texas Medical Branch, Galveston
University of Texas - MD Anderson Cancer Center, Houston
Lead Sponsor
Pfizer
INDUSTRY